Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing novel therapies that can be precisely controlled after delivery, for enhanced efficacy and ultimate safety. BPX-101 is an autologous vaccine in clinical development for patients with prostate cancer, and CaspaCIDeā„¢ DLI is in clinical development for patients undergoing hematopoietic stem cell transplantation.


Date Type Amount Investors Valuation
03/01/12 Series B 20M AAVG Ventures LP, Remeditex Ventures Unknown